Ge Long Hui·2025-08-29 10:25Core Insights - Fosun Pharma has signed a licensing agreement with Aikono for the exclusive rights to research, develop, manufacture, register, and commercialize AC-201 in China and Hong Kong, aimed at treating autoimmune diseases [1][2] - AC-201, an oral small molecule JAK inhibitor developed by Aikono, has shown promising results in Phase II clinical trials for moderate to severe plaque psoriasis, demonstrating good safety and tolerability [1] - The global sales of JAK inhibitors are projected to reach approximately $16.8 billion in 2024, indicating a significant market opportunity for AC-201 [1] Company Overview - Aikono, established in December 2017 and based in Suzhou, Jiangsu Province, focuses on the research and development of small molecule innovative drugs, with three products currently in clinical research [2] - Aikono's registered capital is $43 million, and it is fully owned by Aikono Biopharmaceuticals (Hong Kong) Limited, with Xiaohu Zhang as the actual controller [2] Financial Terms - Fosun Pharma will pay Aikono up to RMB 156 million (including upfront and milestone payments) for the licensing agreement [2] Strategic Implications - This collaboration aims to leverage Fosun Pharma's strengths in drug clinical development, registration, production, and commercialization, enhancing its product pipeline in the autoimmune disease sector and strengthening its competitive position in the market [2]